SCHEMBL16570528

SCHEMBL16570528

CN(c1nccnc1Cn1ncc2cnc(Nc3ccc(N4CCNCC4)cc3)cc21)S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 9/20 0.39
▸ PTK2 Q05397 5/20 0.39
▸ JAK3 P52333 5/20 0.39
▸ FYN P06241 2/20 0.38
▸ BRD4 O60885 6/20 0.38
▸ CDK4 P11802 5/20 0.38
▸ CCND1 P24385 3/20 0.38
▸ FGFR4 P22455 3/20 0.37
▸ FGFR1 P11362 2/20 0.37
▸ CCNA2 P20248 2/20 0.37
▸ FGFR2 P21802 2/20 0.37
▸ FGFR3 P22607 2/20 0.37
▸ CDK2 P24941 2/20 0.37
▸ JAK1 P23458 2/20 0.37
▸ BRD2 P25440 2/20 0.37
▸ BRD3 Q15059 2/20 0.37
▸ BRDT Q58F21 2/20 0.37
▸ CDK6 Q00534 2/20 0.36
▸ WEE1 P30291 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570731 0.90 ROCK2 (0.37) JAK2PTK2JAK3FYNCDK4
SCHEMBL16570729 0.90 ROCK2 (0.37) JAK2PTK2JAK3FYNCDK4
SCHEMBL16580841 0.89 PTK2 (0.46) JAK2PTK2JAK3FYN
SCHEMBL16570558 0.87 STAT6 (0.42) JAK2PTK2JAK3FYNBRD4
SCHEMBL16571341 0.85 CDK4 (0.47) JAK2PTK2JAK3BRD4CDK4
SCHEMBL16570364 0.84 JAK2 (0.44) JAK2PTK2JAK3FYNBRD4
SCHEMBL16570975 0.81 PTK2 (0.51) JAK2PTK2JAK3CCNA2CDK2
SCHEMBL16571037 0.80 PTK2 (0.54) JAK2PTK2JAK3FYNFGFR4
SCHEMBL16571236 0.80 PTK2 (0.42) JAK2PTK2JAK3
SCHEMBL16571232 0.80 PTK2 (0.42) JAK2PTK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN JAK2 9/4885PTK2 2/4885JAK3 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback